A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox.The U.S. Food and Drug Administration wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments.of new treatments not previously approved or marketed in the U.S. The total drugs cleared dipped slightly from 55 in 2023, but there were several firsts and other notable medications that the agency gave a green light last year.
Notably, many of the FDA approvals were for products from a mix of little known public and private companies, such as Allecra Therapeutics,Pharma. It signals that smaller biotech companies are more willing to bring their products to market on their own as opposed to partnering or getting acquired by a large pharmaceutical company.list last year, offers at-risk pricing models to self-insured employers to help their workers quickly access care and navigate benefits.
Transcarent will acquire Accolade for $7.03 per share in cash, which represents a premium of roughly 110% over its closing stock price on Tuesday, Transcarent said. The deal is expected to close next quarter, though it's still subject to shareholder and regulatory approvals. Evercore served as the financial adviser to Transcarent for the deal. Morgan Stanley advised Accolade.